Please login to the form below

Not currently logged in
Email:
Password:

Merck (MSD) expands South African business

Merck (MSD) has entered into a collaboration with Adcock Ingram to co-promote and distribute a number of products in the South African market

Merck (MSD) has entered into strategic collaboration deal with South African company Adcock Ingram. The two companies will co-promote and distribute a selection of prescription products across a number of therapy areas including: asthma, dermatology, hypercholesterolemia, hypertension, migraine and osteoporosis. A number of over-the-counter (OTC) products will also be included in the deal. All of the products are currently registered in South Africa by MSD and Schering-Plough.

Financial details of the deal were not disclosed.

Dr Stefan Oschmann, president, Emerging Markets, MSD said: "We expect sales from these [emerging] markets to be a key contributor to our future performance and growth. As part of our pursuit of that growth we will strive to expand our presence across emerging markets by actively seeking local collaborations." 

Merck expects more than 25 per cent of its global pharmaceutical and vaccine revenue in 2013 to come from emerging markets. The company is the second biggest pharmaceutical company (by revenue) in the world. Its key products include the cholesterol drugs Vytorin (ezetimibe and simvastatin) and Zetia (ezetimibe), and the asthma therapy Singulair (montelukast sodium).

Merck is known as MSD outside of the US and Canada.

24th June 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Say Communications

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...